BMR.H Bradmer Pharmaceuticals

A correction from source is being issued for the press release that was
disseminated at 21:47 ET on July 29, 2010 due to an error in the third paragraph
of the press release. Wildlaw Capital Markets Inc. received warrants exercisable
to acquire 202,631 common shares, and not 215,789 common shares. The complete
and correct release follows.


NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES


Bradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) ("Bradmer" or the
"Corporation") announced today that it has issued and sold, on a private
placement basis, an aggregate 5,263,152 common shares at a price of $0.095 per
share, for aggregate gross proceeds to the Corporation of $500,000.00 (the
"Offering").


The proceeds of the Offering will be used primarily for general corporate
purposes. Completion of the financing is subject to the final approval of the
NEX Board of the TSX Venture Exchange (the "NEX"). The common shares issued
pursuant to the Offering will be subject to a hold period expiring four months
and one day after the closing date of the Offering.


In connection with the Offering, Wildlaw Capital Markets Inc. received a cash
commission of $19,250.00 and warrants exercisable to acquire 202,631 common
shares, at a price of $0.095 per share, for a period of 12 months following the
closing date of the Offering.


The securities offered have not been registered under the United States
Securities Act of 1933, as amended, and may not be offered or sold in the United
States or to, or for the account or benefit of, U.S. persons absent registration
or an applicable exemption from registration requirements. This release does not
constitute an offer for sale of securities in the United States.


Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements regarding a proposed
offering, including the proposed use of proceeds of the offering, and the
proposed listing of the common shares on the NEX. Actual developments may differ
materially from those contemplated by these statements depending upon, among
other things, the ability of the Corporation to raise the funds and decisions
made by securities regulators or stock exchanges. The forward looking statements
contained in this press release represent the Corporation's views and
expectations as of the date of this release and should not be relied upon as
representing its views and expectations at any subsequent date.

Bradmer Pharmaceuticals (TSXV:BMR.H)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Bradmer Pharmaceuticals (TSXV:BMR.H)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024